ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Head & Neck Cancer

Head & Neck Cancer

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.

In this interview we discuss a joint statement from MD Anderson and 68 other NCI-designated cancer centers that calls for increased HPV vaccination for the prevention of cancer.

To date, there is still no strong evidence that induction chemotherapy improves outcomes for locally advanced head and neck cancer.

Dental exams and procedures should occur before treatment begins for patients with head and neck cancer and other malignancies, and post-treatment dental follow-up care should be life-long for cancer survivors.

Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.

Undergoing surveillance with PET/CT resulted in similar survival to planned neck dissection in patients with squamous cell carcinoma of the head and neck with nodal disease who have completed chemoradiotherapy.

The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.

Pages

Subscribe to Head & Neck Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.